NRAS and melanoma: In our study, 29.1 % of the patients (23/79) were concluded to have a NRAS-mutated melanoma (17.7 % (14/79) NRASQ61R, 5.1 % (4/79) NRASQ61Land 6.3 % (5/79) NRASQ61K).